Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Journal of Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by O'Donnell, J.
Right arrow Articles by Kelly, W. N.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Propylene Glycol Toxicity in a Pediatric Patient: The Dangers of Diluents

James O'Donnell

Sue Lyon Mertl

William N. Kelly

This report will present a case of neonatal propylene glycol poisoning from the use of intravenous lorazepam and also discuss the toxicity of diluents in general. Although used as a diluent in many pharmaceuticals and generally considered safe, propylene glycol can cause serious side effects: hyperosmolality in burn victims due to silver sulfadiazine products containing propylene glycol and in premature babies due to particular multivitamin preparations, irreversible perception deafness, skin irritation, high anion gap acidosis due to elevated lactate levels, and reversible neurological disturbances. Toxicity caused by propylene glycol may be manifested by hyperosmolality, lactic acidosis, hemolysis and hemoglobinuria, skin irritation, deafness, and other neurological disturbances.1 Historically, the toxicity of diluents played an important role in the development of toxicity testing before the release of new drugs. The topic is current, as evidenced by the Important Drug Warning letter recently issued by Glaxo Wellcome, the manufacturer of Agenerase, warning about the toxicities and drug interactions associated with the propylene glycol diluent in the oral solution, as well as by competitive interference with the aldehyde dehydrogenase enzyme pathway. This report and discussion is included in the Forensic Pharmacist issue because the case investigation arose out of retention of one of the authors (O'Donnell) as an expert witness and consultant on behalf of the child/subject of the case report.

Key Words: propylene glycol, • lorazepam, • CNS toxicity, • hyperosmolality.

Journal of Pharmacy Practice, Vol. 13, No. 3, 214-225 (2000)
DOI: 10.1177/089719000001300310


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement